The widespread application of GLP-1 receptor agonists at the population level may impose significant financial pressure on pharmaceutical budgets, with modeling studies indicating that treating all eligible individuals with diabetes and obesity might need a 1020% rise in drug expenditures in several nations
CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
Wegovy reduces appetite by mimicking a natural hormone, while Contrave decreases cravings through brain pathways
Regular follow-up with healthcare providers, including A1c testing approximately 3 months after discontinuation for patients with diabetes, is recommended
Signs of injection site infection: increasing redness that spreads beyond the injection area, warmth, swelling that worsens over 24 to 48 hours, pus or discharge, fever, or red streaks extending from the injection site